Apollo Biowellness, Inc., Corporate Update
[ This image cannot be displayed. Please visit the source: https://images.newsfilecorp.com/files/10533/262722_969ba78954e00ae4_001full.jpg ]
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10533/262722_969ba78954e00ae4_001full.jpg
The Company is in final negotiations with an Israeli based Bio-Tech and Biologics manufacturer, listed on NASDAQ, for the co-development of our shelf-stable biologic cosmetic, which is planned to be launched in the 4 th Quarter of 2025. The shelf-stable biologic cosmetic is to be known as Ceilo Skin Care, and will be sold through retail, direct-to-consumer and e-commerce platforms.
In addition, the Company is in negotiations with a large aesthetic company in the business of Laser Energy Devices and products that are marketed and sold to Plastic Surgeons, Dermatologists, Med Spa's and Aesthetic Clinicians. The negotiations are for the purpose of a business combination or potential merger to create a combination therapy company, where we will sell Biologics and Aesthetic devices hand-in-glove.
Also, before the end of the 3 rd Quarter of 2025, Apollo will launch the first of its kind Pet and Veterinarian Biologic, using exosomes and placental products, for Pets, via a Doctor branded product, sold exclusively through licensed Veterinarians, Clinicians and Pet Professionals. This product will be using 100% natural biologic products to treat pets for arthritis issues, joint issues, inflammation issues and skin issues. Our product will include topical and injectable therapeutics.
The Company will be releasing more details as they become relevant regarding these events in the days and weeks to come, and in parallel with these actions, the Company is also working with its Debt Holders and Convertible Note Holders to either restructure, refinance or convert the majority of the positions to a preferred class of equity. This is line with the plan of management to coordinate financing for the Company to allow the plans for growth for the next 12 months.
James W. Zimbler, President and CEO, stated, 'I am very eager for the new start for our biologic products company, along with the potential for new areas of activity. I anticipate an exciting next 12 months for the Company.'
The Company uses the following handle on X at @ApolloBioKOAN to communicate with its shareholders
About Apollo Biowellness, Inc.
Apollo Biowellness, Inc., and its subsidiary, Evolutionary Biologics, Inc., is engaged in the discovery, development and marketing of products designed to better mankind. We believe we are positioning our company as a leader in the field of Regenerative Medicine as defined by the National Institute of Health using biologic based products. Intended products are to be marketed under third-party label exemptions. We are focusing our current efforts on marketing licensed patent-pending natural stem cell mobilizing agents capable of enhancing each individual's ability to mobilize their own adult stem cells from their bone marrow. Also, we are licensed under a patent-pending application to market a dual acting all-natural diet aid designed to help control hunger through normal body signals to the brain and stomach. Products are being developed for consumer and professional markets.
Before using any of our products, you should always consult with your veterinarian and/or family doctor.
Forward-Looking StatementsCorporate Contact
James W. Zimbler
President/CEO/Director
[email protected]
https://evobiologics.com/
631-806-1420
X at @ApolloBioKOAN
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/262722
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 minutes ago
- Yahoo
Masimo sues US Customs over approval of Apple Watch imports
By Blake Brittain WASHINGTON (Reuters) -Medical monitoring technology company Masimo sued U.S. Customs and Border Protection on Wednesday over a decision by the agency that allowed Apple to import Apple Watches with blood-oxygen reading technology during a patent dispute between the companies. Masimo said in the lawsuit in Washington, D.C., federal court that Customs improperly determined that Apple can import watches with pulse oximetry technology, reversing its own decision from last year without notifying Masimo. Masimo told the court that it learned of the agency's August 1 decision only after Apple announced it would reintroduce blood-oxygen reading to its watches last week. Spokespeople for Apple and Customs did not immediately respond to requests for comment. A Masimo spokesperson declined to comment. Irvine, California-based Masimo has accused Apple of hiring away its employees and stealing its pulse oximetry technology to use in its Apple Watches. Masimo has separately sued Apple for patent infringement and trade secret theft in ongoing federal court cases. Masimo convinced the U.S. International Trade Commission to block imports of Apple's Series 9 and Ultra 2 smartwatches in 2023 based on a determination that Apple's technology for reading blood oxygen levels infringed Masimo's patents. Apple has continued to sell Customs-approved redesigned watches without pulse oximetry since the ITC's decision. Apple said on Aug. 14 that it would reintroduce its smartwatches' blood-oxygen reading capabilities with approval from Customs. Masimo said the agency's decision to approve the watches without input from Masimo or any "meaningful justification" deprived the company of its rights. "CBP's function is to enforce ITC exclusion orders, not to create loopholes that render them ineffective," Masimo said. Masimo asked the Washington court to halt the agency's ruling and continue to block Apple from selling watches with the blood-oxygen feature. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10 minutes ago
- Yahoo
Why Medtronic Stock Raced Higher Today
Key Points Investors traded out of the company the previous day following its latest earnings release. The stock came roaring back on Hump Day, however. 10 stocks we like better than Medtronic › A clutch of post-earnings price target increases by analysts helped raise Medtronic's (NYSE: MDT) stock at a healthy rate on Wednesday. The sturdy medical device specialist's shares rose by almost 4% on the day as a consequence, a rate that looked especially good next to the S&P 500's (SNPINDEX: ^GSPC) 0.2% drop. Healthy raises Following a trend that began Tuesday after Medtronic published its first quarter of fiscal 2026 figures. The company posted revenue growth of 8% (to almost $8.6 billion), and improved non-GAAP (generally accepted accounting principles) adjusted net income by 2% to slightly over $1.6 billion. Both headline numbers beat the consensus analyst estimates, albeit not by much. The market, which collectively loves a crushing beat on analyst estimates, basically shrugged at this. Many investors traded out of Medtronic that day. The sun was shining brighter on Wednesday thanks to that series of price target bumps. By my count, seven analysts tracking the stock upped their fair-value assessments. Among these were pundits at such financial industry heavyweights as Wells Fargo, J.P. Morgan, and international bank UBS. Positive moves from cautious pundits I should note that in all cases, those price target raises were incremental. Nevertheless, the raising analysts frequently sounded bullish notes on Medtronic's prospects. One example was Leerink Partners' Mike Kratky, who only added $1 per share for a new level of $111, but maintained his outperform (read: buy) recommendation. According to reports, Kratky praised several elements of the company's operations, particularly its cardiac ablation solutions unit. Less positively, the analyst wrote that Medtronic suffered from weakness in its domestic sales. Should you invest $1,000 in Medtronic right now? Before you buy stock in Medtronic, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Medtronic wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $654,781!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,076,588!* Now, it's worth noting Stock Advisor's total average return is 1,055% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025 Wells Fargo is an advertising partner of Motley Fool Money. Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Medtronic and recommends the following options: long January 2026 $75 calls on Medtronic and short January 2026 $85 calls on Medtronic. The Motley Fool has a disclosure policy. Why Medtronic Stock Raced Higher Today was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10 minutes ago
- Yahoo
Florida sues textbook giants for alleged $60M fraud: '5900 instances of Overcharges,' governor says
The state has filed a lawsuit seeking to claw back millions of dollars from two of the nation's largest textbook publishing companies.
